60 results
8-K
EX-10.1
NMTRQ
9 Meters Biopharma, Inc.
6 Oct 22
Entry into a Material Definitive Agreement
4:15pm
), or a facility for the provision of in-person social, welfare or clinical health services or sleeping accommodations (whether temporary, daytime
8-K
EX-99.2
NMTRQ
9 Meters Biopharma, Inc.
26 Sep 22
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
4:08pm
Pain, Ostomy Leakage, Infusion Schedules, Social Impact2 Influence of Diarrhea on Quality of Life2 “For almost 6 months to a year I wore a diaper
8-K
EX-10.2
y0ccfsckq5wdzceu
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
EX-10.1
3bvx5for 7bwq
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
EX-99.2
732plot2vyehho7
30 Jun 22
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
7:06am
8-K
EX-10.1
67e3fvcca0 jm
22 Jun 22
Departure of Directors or Certain Officers
4:51pm
8-K
EX-99.1
mroy3i9c to0kmlrkvv
10 Nov 21
9 Meters Biopharma, Inc. Announces Immuno-Oncology Collaboration with Gustave Roussy for NM-102, a Gut Microbiome Modulator
7:33am